A Smoking Cessation Treatment for Adult Women

This study has been completed.
Sponsor:
Collaborator:
Information provided by (Responsible Party):
Andrea H. Weinberger, Yale University
ClinicalTrials.gov Identifier:
NCT01422239
First received: August 19, 2011
Last updated: June 6, 2013
Last verified: June 2013
  Purpose

The purpose of this study is to develop and pilot test a smoking cessation counseling that focuses on the perceived risks of quitting smoking (e.g., weight gain, managing cravings and negative affect, loss of enjoyment).

Aim 1: To develop the risk-based smoking cessation intervention.

Aim 2: To examine whether manualized smoking cessation counseling about the perceived risks of quitting is feasible to administer and acceptable to adult women who want to quit smoking.

Aim 3: To examine smoking cessation outcomes for women who receive the risk-based treatment in comparison to standard smoking counseling. It is expected that women who receive risk-based counseling will show better quit rates and a longer time to relapse than women who receive standard treatment.


Condition Intervention Phase
Nicotine Dependence
Behavioral: Tailored treatment
Behavioral: Standard Treatment
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Smoking Cessation Treatment for Adult Women

Resource links provided by NLM:


Further study details as provided by Yale University:

Primary Outcome Measures:
  • Point-prevalence Smoking Abstinence Assessed at the End of the Trial and Measured by Self-report and Confirmed by Carbon Monoxide Levels [ Time Frame: Up to 8 weeks ] [ Designated as safety issue: No ]
    point-prevalence smoking abstinence assessed at the end of the trial and measured by self-report (no smoking reported in the previous 7 days) and confirmed by carbon monoxide levels (CO levels < 5ppm)


Secondary Outcome Measures:
  • Point-prevalence Smoking Abstinence Four Weeks After the End of the Trial Assessed by Self-report and Carbon Monoxide Levels [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
    point-prevalence smoking abstinence assessed at one month after the completion of counseling and measured by self-report (no smoking reported in the previous 7 days) and confirmed by carbon monoxide levels (CO levels < 5ppm)

  • Change in Smoking From Baseline to the Followup Assessment (Week 12) [ Time Frame: Week 0 (baseline), Week 12 (one month followup) ] [ Designated as safety issue: No ]
    Change in number of cigarettes per day (CPD) (averaged over the previous week) from the baseline assessment (Week 0) to the followup assessment (Week 12) for participants who did not quit smoking during the study.


Enrollment: 28
Study Start Date: January 2011
Study Completion Date: December 2012
Primary Completion Date: December 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Tailored behavioral counseling
The focus of the first three sessions for participants receiving the tailored treatment will be their three most highly endorsed perceived risks of quitting. All participants will receive information about preparing for quit day in the second session and coping with withdrawal symptoms in the third session using the Mayo Clinic's "Smoke Free and Living It" manual. The last 5 counseling sessions will be based on perceived risks of quitting.
Behavioral: Tailored treatment
8 sessions of individual behavioral counseling. The first 3 sessions will be 45 minutes long and include 30 minutes tailored to the perceived risks of quitting most strongly held by each participant. The final 5 sessions will be 30 minutes long and include material from the Mayo Clinic's smoking cessation manual.
Active Comparator: Standard behavioral counseling
The focus of the first three sessions for participants receiving the standard treatment will be the benefits of quitting smoking. All participants will receive information about preparing for quit day in the second session and coping with withdrawal symptoms in the third session using the Mayo Clinic's "Smoke Free and Living It" manual. All participants will receive identical counseling sessions during week 4-8 based on material from the Mayo Clinic manual.
Behavioral: Standard Treatment
8 sessions of individual behavioral counseling. The first 3 sessions will be 45 minutes long and include 30 minutes focused on the benefits of quitting smoking. The final 5 sessions will be 30 minutes long and include material from the Mayo Clinic's smoking cessation manual.

Detailed Description:

The purpose of this treatment development study is to design and pilot test a smoking cessation intervention in which counseling sessions are tailored to individual smokers' perceived risks of quitting. The feasibility, acceptability, and efficacy of the novel treatment will be examined through a pilot study in which female smokers will be randomly assigned to receive either the tailored treatment or a standard treatment. It is expected that participants receiving the tailored treatment will show higher rates of smoking abstinence than participants receiving the standard smoking cessation treatment at the end of the 8-week treatment and at one month follow-up.

  Eligibility

Ages Eligible for Study:   18 Years to 64 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Between the ages of 18 and 64 years old
  • Meet Diagnostic and Statistical Manual-IV (DSM-IV) criteria for nicotine dependence with Fagerström Test for Nicotine Dependence (FTND) score ≥4
  • Smoke at least 15 cigarettes (3/4 pack) daily (averaged over 1 week, in the past 1 month) and have an expired breath carbon monoxide (CO) level ≥10
  • At the time of initial evaluation, are motivated to quit smoking in the next 30 days.
  • Have the capacity to give informed consent, and are English-speaking.

Exclusion Criteria:

  • Have a positive urine drug screen or urine pregnancy test at baseline evaluation
  • Meet DSM-IV criteria for alcohol or other drug abuse or dependence in the previous 6 months
  • Meet DSM-IV criteria for a current diagnosis of major depressive disorder, panic disorder or post-traumatic stress disorder
  • Meet DSM-IV criteria for a current or past diagnosis of bipolar disorder or schizophrenia
  • Are currently receiving treatment for nicotine dependence (e.g., nicotine replacement therapy, bupropion, chantix)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01422239

Locations
United States, Connecticut
Yale University School of Medicine, Department of Psychiatry
New Haven, Connecticut, United States, 06519
Sponsors and Collaborators
Yale University
Investigators
Principal Investigator: Andrea H. Weinberger, Ph.D. Yale University
  More Information

No publications provided

Responsible Party: Andrea H. Weinberger, Assistant Professor of Psychiatry, Yale University
ClinicalTrials.gov Identifier: NCT01422239     History of Changes
Other Study ID Numbers: AHW-WHRY-526
Study First Received: August 19, 2011
Results First Received: March 19, 2013
Last Updated: June 6, 2013
Health Authority: United States: Yale Human Investigation Committee

Keywords provided by Yale University:
smoking
treatment
perceived risks

ClinicalTrials.gov processed this record on October 23, 2014